» Articles » PMID: 33459808

Human Family 1-4 Cytochrome P450 Enzymes Involved in the Metabolic Activation of Xenobiotic and Physiological Chemicals: an Update

Overview
Journal Arch Toxicol
Specialty Toxicology
Date 2021 Jan 18
PMID 33459808
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

This is an overview of the metabolic activation of drugs, natural products, physiological compounds, and general chemicals by the catalytic activity of cytochrome P450 enzymes belonging to Families 1-4. The data were collected from > 5152 references. The total number of data entries of reactions catalyzed by P450s Families 1-4 was 7696 of which 1121 (~ 15%) were defined as bioactivation reactions of different degrees. The data were divided into groups of General Chemicals, Drugs, Natural Products, and Physiological Compounds, presented in tabular form. The metabolism and bioactivation of selected examples of each group are discussed. In most of the cases, the metabolites are directly toxic chemicals reacting with cell macromolecules, but in some cases the metabolites formed are not direct toxicants but participate as substrates in succeeding metabolic reactions (e.g., conjugation reactions), the products of which are final toxicants. We identified a high level of activation for three groups of compounds (General Chemicals, Drugs, and Natural Products) yielding activated metabolites and the generally low participation of Physiological Compounds in bioactivation reactions. In the group of General Chemicals, P450 enzymes 1A1, 1A2, and 1B1 dominate in the formation of activated metabolites. Drugs are mostly activated by the enzyme P450 3A4, and Natural Products by P450s 1A2, 2E1, and 3A4. Physiological Compounds showed no clearly dominant enzyme, but the highest numbers of activations are attributed to P450 1A, 1B1, and 3A enzymes. The results thus show, perhaps not surprisingly, that Physiological Compounds are infrequent substrates in bioactivation reactions catalyzed by P450 enzyme Families 1-4, with the exception of estrogens and arachidonic acid. The results thus provide information on the enzymes that activate specific groups of chemicals to toxic metabolites.

Citing Articles

4-Pyridone-3-carboxamide-1-β-D-ribonucleoside Reduces Cyclophosphamide Effects and Induces Endothelial Inflammation in Murine Breast Cancer Model.

Mierzejewska P, Denslow A, Papiernik D, Zabrocka A, Kutryb-Zajac B, Charkiewicz K Int J Mol Sci. 2025; 26(1.

PMID: 39795893 PMC: 11719935. DOI: 10.3390/ijms26010035.


Role Assessment of Water-Soluble Pharmaceutical Form of Phosphatidylcholine on the Catalytic Activity of Cytochrome P450 2C9 and 2D6.

Koroleva P, Bulko T, Kuzikov A, Gilep A, Romashova Y, Tichonova E Int J Mol Sci. 2025; 26(1.

PMID: 39795865 PMC: 11720032. DOI: 10.3390/ijms26010004.


Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review.

Mokhosoev I, Astakhov D, Terentiev A, Moldogazieva N Cells. 2024; 13(23).

PMID: 39682707 PMC: 11639897. DOI: 10.3390/cells13231958.


GTransCYPs: an improved graph transformer neural network with attention pooling for reliably predicting CYP450 inhibitors.

Zonyfar C, Ngnamsie Njimbouom S, Mosalla S, Kim J J Cheminform. 2024; 16(1):119.

PMID: 39472986 PMC: 11524008. DOI: 10.1186/s13321-024-00915-z.


Designing cytochrome P450 enzymes for use in cancer gene therapy.

Carrera-Pacheco S, Mueller A, Puente-Pineda J, Zuniga-Miranda J, Guaman L Front Bioeng Biotechnol. 2024; 12:1405466.

PMID: 38860140 PMC: 11164052. DOI: 10.3389/fbioe.2024.1405466.


References
1.
Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M . Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol. 2002; 61(3):586-94. DOI: 10.1124/mol.61.3.586. View

2.
Al-Subeihi A, Alhusainy W, Kiwamoto R, Spenkelink B, van Bladeren P, Rietjens I . Evaluation of the interindividual human variation in bioactivation of methyleugenol using physiologically based kinetic modeling and Monte Carlo simulations. Toxicol Appl Pharmacol. 2015; 283(2):117-26. DOI: 10.1016/j.taap.2014.12.009. View

3.
Alvarez-Diez T, Zheng J . Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol. Chem Res Toxicol. 2004; 17(2):150-7. DOI: 10.1021/tx034143l. View

4.
Amato G, Grasso E, Longo V, Gervasi P . Oxidation of N,N-dimethylformamide and N,N-diethylformamide by human liver microsomes and human recombinant P450s. Toxicol Lett. 2001; 124(1-3):11-9. DOI: 10.1016/s0378-4274(01)00324-1. View

5.
Aoyama T, Gonzalez F, Gelboin H . Human cDNA-expressed cytochrome P450 IA2: mutagen activation and substrate specificity. Mol Carcinog. 1989; 2(4):192-8. DOI: 10.1002/mc.2940020405. View